Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
March 19, 2020
Date of Patent:
July 27, 2021
Assignee:
Five Eleven Pharma Inc.
Inventors:
Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
February 9, 2021
Assignee:
FIVE ELEVEN PHARMA INC.
Inventors:
Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
March 19, 2020
Publication date:
July 23, 2020
Applicant:
Five Eleven Pharma Inc.
Inventors:
Zehui WU, Zhihao ZHA, Futao LIU, Karl PLOESSL, Seok Rye CHOI, Hank F. KUNG
Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 20, 2016
Date of Patent:
June 23, 2020
Assignee:
FIVE ELEVEN PHARMA INC.
Inventors:
Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
April 9, 2019
Assignee:
Five Eleven Pharma Inc.
Inventors:
Hank F. Kung, Zehui Wu, Seok Rye Choi, Karl Plössl, Zhihao Zha
Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
July 6, 2016
Publication date:
January 26, 2017
Applicant:
Five Eleven Pharma Inc.
Inventors:
Hank F. KUNG, Zehui Wu, Seok Rye Choi, Karl PLÖSSL, Zhihao Zha